HOPKINTON, Mass., Aug. 31, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP) today announced the availability of the IVIS Spectrum CT, a breakthrough preclinical imaging system that integrates, into a single instrument system, advanced optical imaging and low dose microCT (micro computed tomography). Spectrum CT enables simultaneous molecular and anatomical longitudinal studies, providing researchers with vital, unparalleled insights into complex biological systems in small animal models used to develop new, clinically translatable discoveries. A broad array of applications exist for the new instrument, with musculoskeletal, vascular, oncology, phenotyping, cardiovascular and respiratory disease among those areas particularly enabled by the integration of optical and microCT imaging.
The Spectrum CT expands upon the versatility and advanced optical features of the Caliper IVIS and Maestro platforms, the leading preclinical optical imaging technologies with over 1250 instruments placed worldwide. The system offers powerful, flexible and exquisitely sensitive optical molecular imaging integrated with complementary, ultra-fast, low-dose microCT anatomical imaging. Features include optical sensitivity capable of achieving detection of a few cells and 3-dimensional reconstructions of optical molecular bioluminescence and fluorescence signals, integrated with 3-dimensional anatomical microCT images. Designed for high-throughput, quantitative, non-invasive longitudinal analysis of large cohorts of animals, Spectrum CT enables new, clinically translatable insights. Regarding one example application, Lloyd Miller, MD., PhD., Assistant Professor at UCLA Departments of Medicine and Orthopaedic Surgery commented, "The Spectrum CT provided extraordinary 3-dimensional images of bacteria and infection-induced inflammation in implant biofilms and the anatomical interactions between bone and the implant. This is achieved noninvasively in the same mice and in real-time. The instrument represents a major advance in the field of in vivo imaging and we are excited about the opportunity to use the Spectrum CT for our research."
"IVIS Spectrum CT is a revolutionary platform, the result of continued innovation by Caliper in response to the unmet research and translational needs of our customers," said Kevin Hrusovsky, President and Chief Executive Officer of Caliper Life Sciences. "The fertile preclinical research arena continues to push the boundaries to our understanding of disease, while directly impacting development of new personalized therapies and related companion diagnostics. Our focus on high-quality, quantitative imaging and analysis systems enables critical research by providing insight and context to functional and anatomical events that are relevant to clinical research, drug development and diagnostics."
Caliper will deliver technical presentations on the IVIS Spectrum CT on September 6 at Caliper's West Coast COG meeting and will unveil the platform at the World Molecular Imaging Congress in San Diego on September 7 (Booth 102). For additional information regarding IVIS Spectrum CT please visit: www.CaliperLS.com/SpectrumCT. Visit www.CaliperLS.com/ivis to learn more about Caliper's complete line of in vivo imaging solutions including optical and microCT systems, along with a full suite of applications and reagents.
About Caliper Life Sciences
Caliper is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling researchers to translate those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, tissue microscopy, preclinical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.
SOURCE Caliper Life Sciences, Inc.